

Thermo Fisher Scientific and Telangana govt to establish bioprocess design centre for novel biotherapeutics

27 October 2024 | News

State-of-the-art facility to accelerate research and development in biopharma and biotechnology



Thermo Fisher Scientific has announced the signing of a Memorandum of Understanding (MoU) with the Government of Telangana to establish a Bioprocess Design Centre (BDC) in Genome Valley, Hyderabad.

Totalling 10,000 sq. ft., the Bioprocess Design Centre will become operational in early 2025 and serve as a benchmark to accelerate the development and manufacturing of innovative biotherapeutics in India and Asia-Pacific region. The Centre will feature state-of-the-art labs as well as training hubs to drive scientific research.

Duddilla Sridhar Babu, Minister for ITE&C and I&C Departments, commented, "The establishment of this Bioprocess Design Centre reflects the state's progressive policies and collaborative approach to building a robust biopharma infrastructure. With over 1,800 companies, Telangana is leading the way in making India a global hub for biopharma innovation."

Thermo Fisher will equip the centre with advanced workflow capabilities across upstream and downstream research, cell culture media development, single-use scale-up manufacturing, and product validation.

Tony Acciarito, President, APJ, Thermo Fisher Scientific, said, "Our partnership with the Government of Telangana will strengthen India's biopharma manufacturing capabilities, accelerating the development of breakthrough therapeutics and advancing healthcare solutions that will benefit patients globally."

Earlier this year, Thermo Fisher also partnered with leading bio-incubators to set up five Centres for Innovation at Centre for Cellular and Molecular Platforms (C-CAMP), Bengaluru, Atal Incubation Centre - Centre for Cellular Molecular Biology (AIC-CMB), Hyderabad, Aspire Bionest, Hyderabad, IIT Bionest, Guwahati and KIIT-TBI, Bhubaneswar. These centres are providing startups access to Thermo Fisher's advanced technologies and expertise, significantly reducing the time to market for new biopharma products.